Effect of dopaminergic therapy on cognitive function in patients with Parkinson’s disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Parkinson’s disease (PD) is a neurodegenerative disease with a chronic progressive course, which is caused by irreversible degenerative changes in dopaminergic neurons in the substantia nigra with a decrease in dopamine levels in the basal ganglia. Until now, PD remains an incurable disease, but the available therapeutic arsenal significantly alleviates the symptoms of the disease. The emergence of certain difficulties in identifying PD at the early stages of the disease leads to a decrease in the effectiveness of treatment, and, on the contrary, the positive effectiveness of PD treatment will depend on the timely and correct diagnosis. Severity of the condition, age criteria and individual characteristics should be taken into account in the therapeutic approach for PD. In PD motor and autonomic symptoms dominate, but neurocognitive impairments such as information acquisition, processing and analysis are also significant. According to some researchers, at the initial stage of PD in patients under 70 years of age, dementia was detected in 17%, and after 70 years - in 83% of cases. When patients perform neuropsychological tests, the cognitive status improves due to the replenishment of dopamine deficiency in the striatum, activation of dopamine receptors through the restoration of the functioning of the fronto-striatal circles, which leads to a decrease in dysfunction of the frontal lobes.

Full Text

Restricted Access

About the authors

Yu. I Khabarova

Yakutsk Scientific Center for Complex Medical Problems

Email: september062007@mail.ru
Junior Researcher, Head of the Neurological Department of the Center for Neurodegenerative Diseases

A. A Tappakhov

Yakutsk Scientific Center for Complex Medical Problems; M.K Ammosov North-Eastern Federal University

T. E Popova

Yakutsk Scientific Center for Complex Medical Problems

References

  1. Ершова М.В., Иванова Е.О., Иллариошкин С.Н. Болезнь Паркинсона и нейротрофический гомеостаз. Нервные болезни. 2018;1:3-9. doi: 10.24411/2071-5315-2018-11991.
  2. Ciarke C.E. Does ievodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord. 1995;10:250-56. Doi: 10.1002/ mds.870100303.
  3. Голубев В.Л. Лечение болезни Паркинсона: решенные и нерешенные вопросы. В. кн.: Избранные лекции по неврологии. Под ред. В.Л. Голубева. M., 2006. С. 395-421.
  4. Katzenschlager R., Lees A. Treatment of Parkinsons disease: levodopa as the first choice. J. Neurol. 2002;249(Suppl. 2):19-24. Doi: 10.1007/ s00415-002-1204-4.
  5. Левин О.С., Артемьев Д.В., Бриль Е.В., Кулуа Т.К. Болезнь Паркинсона: современные подходы к диагностике и лечению. Практическая медицина. 2017;1(102):45.
  6. Таппахов А.А., Попова Т. Е., Николаева Т. Ю. и др. Нейропсихологическая картина болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2017;9(4):82-87.
  7. Hughes A.J., Daniel S.E., Kilford L., lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: aclinico-pathological study of 100 cases. J. Neurol Neurosurg Psychiatry. 1992;55:181-84. doi: 10.1136/jnnp.55.3.181.
  8. Иллариошкин С.Н. Современные подходы к лечению болезни Паркинсона. Атмосфера. Нервные болезни. 2004;4:14.
  9. Шнайдер Н.А., Сапронова М.Р. Моногенные формы болезни Паркинсона. Вестник клинической больницы № 51. 2012;5(1-3):14.
  10. Левин О.С., Федорова Н.В. Болезнь Паркинсона. 3-е изд. М.: 2012. С. 31: ил.
  11. Fahn S. Parkinsonism. Complications of long-term levodopa therapy. In: L.P. Ronald, editor. Merritt’s Textbook of Neurology. 9th ed. New York, Williams & Wilkins. 1995. 726 р.
  12. Ахметжанов В.К., Шашкин Ч.С., Джамантаева Б.Д. Болезнь Паркинсона. Патофизиология экстрапирамидной системы. Современные представления о причинах возникновения и патогенезе паркинсонизма. Нейрохирургия и Неврология. Казахстан. 2016;2(43):44-
  13. Скоромец А.А., Тимофеева А.А., Алиев К.Т. и др. Когнитивные функции при болезни Паркинсона и паркинсонизме, их коррекция Пронораном. Эффективная фармакотерапия. Клинические исследования. 2014;17:8.
  14. Ferreira J.J., Katzenschlager R., Bloem B.R., et al. Summary of the recommendations of the EFNS/MDS-ES review on theraputic management of PD. Eur J. Neurol. 2013;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x
  15. Раздорская В.В., Юдина ГК. Болезнь Паркинсона: фармакотерапевтические аспекты амбулаторно-поликлинического этапа. Bull Med Intern Conferenc. 2015;5(3).
  16. Рудакова А.В., Левин О.С. Фармако-экономические аспекты комбинированной терапии развернутой стадии болезни Паркинсона. Нервные болезни. 2017. С. 30-4.
  17. Miller D.W., Abercrombie E.D. Role of high-affinity dopamine uptake activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopaminetreated rats. J. Neurochem. 1999;72:1516-22. doi: 10.1046/j.1471-4159.1999.721516.x.
  18. Tanaka H., Kannari K., Maeda T., et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 1999;10:631-4. doi: 10.1097/00001756-199902250-00034.
  19. Yamato H., Kannari K., Shen H., et al. Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport. 2001;12:1123-6. doi: 10.1097/00001756200105080-00015.
  20. Shohamaya D., Myersb E. Catherine., et al. The role of dopamine in cognitive sequence learning: evidence from Parkinson’s disease. Behavioural Brain Research. Res Report. 2005;156:191-9. doi: 10.1016/j.bbr.2004.05.023.
  21. Brown, R.G., Marsden, C.D. Cognitive function in Parkinson's disease: From description to theory. Trends in Neurosciences. 1990;13(1):26. doi: 10.1016/0166-2236(90)90058.
  22. Brusa L., Bassi A., Stefani A., et al. Pramipexole in comparison to l-dopa: a neuropsychological study. Stanzione (2003). J. Neural Transm. 2003;110:373-380. doi: 10.1007/s00702-002-0811-7.
  23. Miah P.I., Olde Dubbelink K.T., Stoffers D., et al. Early-stage cognitive impairment in Parkinson Os disease and the influence of dopamine replacement therapy. Department of Neurology, VU University Medical Center (VUMC), Amsterdam; and Department of Clinical Neuropsychology, VU University, Amsterdam, The Netherlands. https://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2011.03578.x.
  24. Бугрова С.Г., Новиков А.Е. Когнитивные нарушения и функция нейромедиаторных систем при дисциркуляторной энцефалопатии с учетом результатов лечения Пронораном. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007:8;63-5.
  25. Пилипович А.А. Умеренные когнитивные расстройства: роль Пронорана в их коррекции. Consilium Medicum. Неврология и ревматология. 2017;19:38-42. doi: 10.26442/2075-1753_19.2. 3.38-42.
  26. Elmer L., Schwid S., Eberly S., et al.; Parkinson Study Group TEMPO, PRESTO Investigators. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J. Neurol Sci. 2006;248(1-2):78-83. doi: 10.1016/j.jns.2006.05.014.
  27. Rascol O., Fitzer-Attas C.J., Hauser R., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415-423. doi: 10.1016/s1474-4422(11)70073-4.
  28. Dixit S.N., Behari M., Ahuja G.K. Effect of selegiline on cognitive functions in Parkinson's disease. Clin Trial J. Assoc Phys India. 1999;47(8): 7884-6.
  29. Parkinson's disease Diagnosis and management in primary and secondary care. Developed by the National Collaborating Centre for Chronic Conditions. National Inst. Health Clin Excell. 2006;35:1-45.
  30. Иллариошкин С.Н. Основные принципы тера пии болезни Паркинсона. Неврология. Русский медицинский журнал. 2004;10:604. [Illarioshkin S.N. Basic principles of therapy for Parkinson’s disease. Neurology. Russkii meditsinskii zhurnal. 2004;10:604.
  31. Садеков РА., Вейн М. Лечение паркинсонизма: монография. М., 2001. 96 c.
  32. Hanna-Pladdy B., Jonet K., Cabancan R., et al. Predictors of Mild Cognitive Impairment in Early-Stage Parkinson's Disease. Dement Geriatr Cogn Disord Extra. 2013;3:168- 78. doi: 10.1159/000351421.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies